+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating ASTX030, an oral azacitidine AZA formulation combined with cedazuridine CED tablets, in patients with Myelodysplastic Syndrome MDS. This Phase 1 study aims to identify doses of these oral formulations that achieve a similar total exposure AUC to that of the standard subcutaneous AZA injection at 75 mgm2, including separate parts focusing on tolerability and expansion assessments. During the tolerability assessment part, patients receive subcutaneous AZA on Day 1 of Cycle 1 followed by oral AZA and CED on Days 2 to 7, with oral dosing continued on Days 1 to 7 in subsequent cycles. The expansion assessment part uses a crossover design where patients alternate between ASTX030 and subcutaneous AZA in the first two cycles, then continue ASTX030 from Cycle 3 onward, with each cycle lasting 28 days. Participants will be monitored through pharmacokinetic measurements comparing total AUC of AZA between oral and injection forms up to 2 months for the expansion part and up to 1 month for the tolerability part. Safety and tolerability are assessed, and participants must meet specific organ function and performance status criteria. The study spans multiple cycles with scheduled dosing and evaluations to compare the investigational oral treatment to standard injection therapy.

Age: 20Years +All GendersPhase 1
10 locations
P

Actively Recruiting

Researchers are evaluating whether baricitinib can delay the onset of clinical type 1 diabetes T1D in children and adults who are at high risk of developing this condition. This Phase 3, double-blind, randomized, placebo-controlled study includes participants aged 1 to less than 36 years with early-stage type 1 diabetes or specific diabetes-related autoantibodies. The study is sponsored by Eli Lilly and Company and aims to understand if baricitinib can postpone progression to stage 3 T1D. Participants will be randomly assigned to receive either baricitinib or a placebo orally. The intervention period may last up to approximately 5 years, during which the time from baseline to diagnosis of stage 3 type 1 diabetes will be closely monitored. Both groups will be followed to assess changes in glucose metabolism, C-peptide levels, body measurements, and quality of life. During the study, participants will undergo regular assessments including blood tests to measure glucose-stimulated C-peptide, glucose levels, and other metabolic markers at baseline and after one year. Additional evaluations include body height, body mass index percentile, and health surveys. Pharmacokinetics of baricitinib will also be monitored up to week 24. Safety and efficacy data will be collected throughout the study period, lasting up to approximately 5 years per participant.

Age: 1Year - 35YearsAll GendersPhase 3
112 locations
S

Actively Recruiting

Researchers are evaluating baricitinib to see if it can preserve beta-cell function in children and adults newly diagnosed with type 1 diabetes. This Phase 3 randomized, double-blind, placebo-controlled study includes participants aged 1 to under 36 years who have been recently diagnosed with type 1 diabetes. The study aims to understand the impact of baricitinib on insulin-producing cells to potentially support better diabetes management. Participants will be randomly assigned to receive either oral baricitinib or a placebo. The treatment period lasts up to 52 weeks, during which participants will take their assigned study medication regularly. The study compares the effects of baricitinib against placebo to assess preservation of beta-cell function and related outcomes. Throughout the approximately 60-week participation, individuals will undergo multiple assessments including measuring C-peptide levels, hemoglobin A1c, insulin use, hypoglycemic events, growth parameters, and quality of life surveys. Safety and drug levels will also be monitored. These evaluations help researchers determine how the study drug affects diabetes control and participant health over time.

Age: 1Year - 35YearsAll GendersPhase 3
130 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.

Age: 18Years - 75YearsAll GendersPhase 2
87 locations
C

Actively Recruiting

Researchers are evaluating the medicine orforglipron compared to dulaglutide in children and teenagers aged 10 to less than 18 years who have type 2 diabetes. The study aims to understand how well these medicines work, how safe they are, and how the body processes them. This trial is a Phase 3 randomized study that focuses on treatment for pediatric participants with this condition. Participants will be randomly assigned to receive either orforglipron orally once daily or dulaglutide by subcutaneous injection once weekly. The study treatment period lasts about 40 weeks, with monitoring extending up to 61 weeks. Both medicines are being assessed for their effects on blood sugar control and other health measures during this time. Participants will be involved in regular visits for evaluations, including blood tests to measure hemoglobin A1c and other health indicators such as body weight, blood pressure, and cholesterol. Researchers will also monitor safety and how the medicines are processed in the body. Overall participation in the study will last approximately 61 weeks, during which participants will receive ongoing assessments to track treatment outcomes.

Age: 10Years - 17YearsAll GendersPhase 3
71 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of two drug combinations for adults with relapsed or refractory multiple myeloma, a type of blood cancer. This study compares mezigdomide combined with bortezomib and dexamethasone MeziVd against pomalidomide combined with bortezomib and dexamethasone PVd in participants who have received one to three previous therapies including lenalidomide. The goal is to find out which treatment better controls the disease and how well patients tolerate these combinations. Participants are randomly assigned to receive either MeziVd or PVd treatment. Each drug is given at specified doses on certain days, and the study is open-label, meaning both participants and researchers know the assigned treatment. The study lasts up to approximately five years, allowing long-term monitoring and assessment of disease progression and survival. Additional measurements include drug levels in the blood, response rates, quality of life questionnaires, and safety evaluations. During the study, participants will have regular assessments to monitor their disease status, treatment response, and side effects. Progression-free survival, the time until disease worsens or death, is the main outcome measured. Other outcomes include overall survival, response quality, time to next treatment, and quality of life changes. Safety is closely monitored through adverse event reporting. The study provides important data to understand how these drug combinations work in relapsed or refractory multiple myeloma over an extended period.

Age: 18Years +All GendersPhase 3
266 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of KarXT for treating manic episodes in adults with Bipolar-I Disorder. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults experiencing an acute episode of mania or mania with mixed features. The study aims to compare KarXT to placebo during a 3-week inpatient treatment period to assess symptom improvement. Participants will be randomly assigned to receive either KarXT or a placebo with flexible dosing during the 3-week inpatient phase. Prior to treatment, participants must undergo a screening period and psychotropic medications must be washed out within 14 days before starting. After the treatment phase, there is a safety follow-up period, with the entire study lasting no more than seven weeks. During the study, participants will be hospitalized for close monitoring. Researchers will assess symptoms using the Young Mania Rating Scale and Clinical Global Impressions-Bipolar at baseline and week 3. Safety evaluations will continue through follow-up visits. The main outcome is the change in mania symptoms after 3 weeks of treatment, with additional measures of clinical response and safety observed throughout the study.

Age: 18Years - 65YearsAll GendersPhase 3
74 locations
R

Actively Recruiting

Researchers are evaluating the effects of teplizumab compared with a placebo in individuals aged 1 to 25 years who have recently been diagnosed with Stage 3 type 1 diabetes. This Phase 3, multicenter, randomized, double-blind study aims to measure changes in blood sugar control and the ability to reduce prandial insulin use over 52 weeks. Both groups will continue their standard insulin therapy during the study. Participants will receive either teplizumab or a matching placebo through intravenous infusions, with teplizumab doses gradually increasing. The study includes two groups one receiving the study drug and the other receiving placebo infusions. The total study period for each participant lasts about 84 weeks 19 months, during which participants are closely monitored. Throughout the study, participants will be regularly evaluated for blood sugar levels, insulin use, and markers of diabetes control including glycated hemoglobin HbA1c, C-peptide levels, and glucose monitoring. Safety will be assessed by tracking adverse events and immune responses. The research team will monitor participants at specified intervals up to 78 weeks to assess treatment effects and safety.

Age: 1Year - 25YearsAll GendersPhase 3
202 locations
E

Actively Recruiting

Researchers are evaluating GB-0895 as an add-on therapy for adolescents and adults with severe asthma that remains uncontrolled despite using inhaled corticosteroids and other asthma controllers. This global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study aims to assess the effectiveness and safety of GB-0895 in improving asthma outcomes. Participants will receive either GB-0895 or a placebo through subcutaneous injections every six months during the treatment period. The study includes a screening and run-in phase from weeks -5 to 0, a treatment phase lasting 52 weeks, and a follow-up phase lasting from week 52 to week 90. An optional open-label extension allows continued GB-0895 treatment from week 52 through week 142. During the study, participants will undergo various assessments including lung function tests, questionnaires about asthma symptoms and quality of life, and monitoring for asthma exacerbations and adverse events. Researchers will measure outcomes such as the annual rate of asthma exacerbations and changes in lung function over 52 weeks. Safety evaluations will continue throughout treatment and follow-up. The total participation duration may extend up to nearly three years if the optional extension is chosen.

Age: 12Years - 80YearsAll GendersPhase 3
158 locations

1-10 of 12

1